The 44th CCII Seminar “Uncovering the Basic Residue-Rich Sequence: from immunoreceptor signaling to immunotherapy” (Chenqi Xu)｜Events｜Center for Cancer Immunotherapy and Immunobiology

The 44th CCII Seminar “Uncovering the Basic Residue-Rich Sequence: from immunoreceptor signaling to immunotherapy” (Chenqi Xu)

Date, Time & Venue

November 18, 2025 (Tue), 15:00-16:00
Venue: NITORI HALL, Bristol Myers Squibb Building 1F
On-site participation, admission free
Organizer: Center for Cancer Immunotherapy and Immunobiology (CCII)

Speaker

Dr. Chenqi Xu

Professor / Deputy Director
Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences

Abstract

The Basic Residue-Rich Sequence (BRS) is a conserved signaling motif widely present in immunoreceptors but remains poorly understood. By forming electrostatic networks with charged lipids and proteins near the membrane, BRS regulates phosphorylation, ubiquitination, condensation, and mechanotransduction. It also coordinates with tyrosine-based motifs to define immunoreceptor function. Evidence from animal and clinical studies shows that harnessing BRS signaling enhances T-cell persistence and sensitivity, unveiling a new avenue for designing next-generation immunotherapies.